Related Experiment Video
Updated: Jun 12, 2026

Isolation of Low Endotoxin Content Extracellular Vesicles Derived from Cancer Cell Lines
Published on: February 17, 2023
Extracorporeal removal of endotoxin: the polymyxin B-immobilized fiber cartridge
Abstract:
Endotoxin, which consists of lipopolysaccharide (LPS), is an outer membrane component of the Gram-negative bacterial cell wall. Endotoxin in the blood stream from an infectious focus or through translocation from the gut plays an important role in the pathogenesis of severe sepsis and septic shock. It binds to monocytes and macrophages, activating them to trigger the production of a variety of mediators. These mediators injure endothelial cells and induce microcirculatory dysfunction. This leads to subsequent organ dysfunction and multiorgan failure. The neutralization or elimination of endotoxin in the blood is an enticing approach for treating severe sepsis and septic shock. Selective adsorbent therapy targeting blood endotoxin has been clinically applied for more than 15 years, mainly in Japan and more recently in Italy and other countries. Toraymyxin(TM) (PMX;Toray, Tokyo, Japan) is a selective blood endotoxin removal cartridge. PMX is composed of polymyxin B (PL-B) covalently bonded to polystyrene-derivative fibers. It is well known that PL-B binds endotoxin and has bactericidal activity. PL-B has a strong affinity to endotoxin and is able to bind the lipid A portion of endotoxin through ionic and hydrophobic interactions. Intravenous injection of PL-B has significant nephrotoxic and neurotoxic effects. However, covalently immobilized PL-B on the adsorbents of PMX do not leak out into the blood stream, thus allowing the clinical application without the known toxic effects of PL-B. Within each cartridge, an adsorbent structure made of PL-B-fixed fabrics is included. Blood flow direction is well controlled by adopting a radial flow system. PMX treatment occurs by hemoperfusion at a blood flow rate of about 80-120 ml/min. Heparinis preferably used as an anticoagulant. In Japan, PMX has been clinically used since 1994under the national health insurance system. It is estimated that over 80,000 patients have received PMX treatment in Japan. Not only has PMX been clinically used safely in Japan, but also in other countries.
Insights
Endotoxin (lipopolysaccharide) removal using Toraymyxin (PMX) cartridges effectively treats severe sepsis and septic shock by eliminating bacterial toxins from the blood, preventing organ failure.
Area of Science:
- Biomedical Engineering
- Immunology
- Critical Care Medicine
Background:
- Endotoxin (lipopolysaccharide, LPS) from Gram-negative bacteria is a key factor in severe sepsis and septic shock pathogenesis.
- LPS activates immune cells, leading to mediator release, endothelial damage, and multiorgan failure.
- Eliminating blood endotoxin is a promising therapeutic strategy for sepsis.
Purpose of the Study:
- To describe the selective endotoxin removal therapy using Toraymyxin (PMX) cartridges.
- To highlight the mechanism, safety, and clinical application of PMX in treating endotoxemia.
Main Methods:
- PMX is a hemoperfusion cartridge using polymyxin B (PL-B) immobilized on fibers to bind endotoxin.
- PL-B binds the lipid A portion of LPS via ionic and hydrophobic interactions.
- Treatment involves hemoperfusion at 80-120 ml/min, often with heparin anticoagulation.
Main Results:
- Covalently immobilized PL-B in PMX avoids systemic toxicity associated with free PL-B.
- PMX has been used clinically in Japan since 1994, with over 80,000 patients treated.
- The therapy has demonstrated safe and effective clinical application in multiple countries.
Conclusions:
- Selective endotoxin removal with PMX offers a safe and effective approach to managing severe sepsis and septic shock.
- PMX cartridges provide a targeted therapy to mitigate the harmful effects of endotoxemia.
- Continued clinical use and research support PMX as a valuable tool in critical care for endotoxin-mediated diseases.
Related Concept Videos
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Drug Elimination by Renal Route: Tubular Secretion

